ALNYLAM PHARMACEUTICALS INC (ALNY)       233.37  +3.62 (+1.58%)

233.37  +3.62 (+1.58%)

US02043Q1076 - Common Stock - After market: 238.07 +4.7 (+2.01%)


Fundamental Rating

3

Overall ALNY gets a fundamental rating of 3 out of 10. We evaluated ALNY against 641 industry peers in the Biotechnology industry. The financial health of ALNY is medium. Also its profitability is quite bad. ALNY shows excellent growth, but is valued quite expensive already.

Note: ALNY has only limited data available, so a full analysis was not possible, which makes the total rating unfair.




Profitability

Profitability Rating

0

ALNY has a very weak Piotroski-F score of 2.00. This is an indication of health and profitability issues for ALNY.

VS Industry

Valuation

Valuation Rating

0

The Price/Earnings Ratio is negative for ALNY. In the last year negative earnings were reported.

Also next year ALNY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
VS Industry

Growth

Growth Rating

7

ALNY is expected to show a strong growth in Earnings Per Share. In the coming 5 years, the EPS will grow by 27.20% yearly.
The Revenue has grown by 28.23% in the past year. This is a very strong growth!
The Revenue has been growing by 78.04% on average over the past 5 years. This is a very strong growth!

Based on estimates for the next 5 years, ALNY will show a very strong growth in Revenue. The Revenue will grow by 35.97% on average per year.
The earnings per share for ALNY have decreased strongly by -29.65% in the last year.
The Revenue growth is decreasing: in the next 5 years the growth will be less than in the last years.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A -29.65% -35.43% 9.26% 21.57% 27.2%
Revenue78.04% 124.22% 28.23% 23.25% 34.71% 38.96% 35.97%

Health

Health Rating

4

ALNY has a Current Ratio of 3.48. This indicates that ALNY is financially healthy and has no problem in meeting its short term obligations.
ALNY has a Quick Ratio of 3.33. This indicates that ALNY is financially healthy and has no problem in meeting its short term obligations.
The Altman-Z score of ALNY is much better than the industry average of -0.10.
ALNY has an Altman-Z score of 2.45. This is not the best score and indicates that ALNY is in the grey zone with still only limited risk for bankruptcy at the moment.

When comparing the Current Ratio of ALNY to the average industry Current Ratio of 6.18, ALNY is less able to pay its short term obligations than its industry peers.
Compared to an average industry Quick Ratio of 6.05, ALNY is worse placed to pay its short term obligations than its industry peers.
ALNY has a very weak Piotroski-F score of 2.00. This is an indication of health and profitability issues for ALNY.
VS Industry

Quick Ratio (3.33) VS Industry: 28% outperformed.

0.04
84.53

Current Ratio (3.48) VS Industry: 29% outperformed.

0.08
85.09

Altman-Z (2.45) VS Industry: 66% outperformed.

-2,801.75
658.20

Dividend

Dividend Rating

0

No dividends for ALNY!.

ALNYLAM PHARMACEUTICALS INC233.37

NASDAQ:ALNY (2/3/2023, 7:24:31 PM)+3.62 (+1.58%)

After market: 238.07 +4.7 (+2.01%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Biotechnology
Earnings (Last) 10-27 2022-10-27/bmo Earnings (Next) 02-08 2023-02-08/amc
Inst Owners 103.41% Inst Owner Change -1.46%
Ins Owners 0.06% Ins Owner Change 9.75%
Market Cap 28.71B Analysts 79.38
Price Target 247.91 (6.23%)

Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y) N/A DP N/A
Div Incr Years N/A Div Non Decr Years N/A
Ex-Date N/A

Surprises & Revisions
EPS beat(2) N/A Avg EPS beat(2) -43.38%
Min EPS beat(2) -49.37% Max EPS beat(2) -37.39%
EPS beat(4) N/A Avg EPS beat(4) -32.7%
Min EPS beat(4) -49.37% Max EPS beat(4) -6.57%
Revenue beat(2) N/A Avg Revenue beat(2) -12.52%
Min Revenue beat(2) -13.86% Max Revenue beat(2) -11.18%
Revenue beat(4) 1 Avg Revenue beat(4) -7.66%
Min Revenue beat(4) -14.09% Max Revenue beat(4) 8.49%
PT rev (1m) 0.45% PT rev (3m) 2.12%
EPS NQ rev (1m) -7.11% EPS NQ rev (3m) -10.2%
EPS NY rev (1m) 0% EPS NY rev (3m) -26.48%
Revenue NQ rev (1m) 0.25% Revenue NQ rev (3m) -0.7%
Revenue NY rev (1m) 0% Revenue NY rev (3m) -1.41%

Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 29.88
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM) -9.14 EY N/A
EPS(NY) -5.74 Fwd EY N/A
FCF(TTM) -5.13 FCFY N/A
OCF(TTM) -4.55 OCFY N/A
SpS 7.81 BVpS -0.55
TBVpS -0.55 PEG (NY) N/A
PEG (5Y) N/A

Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM N/A
GM 83.85%
ROICexgc(3y) N/A ROICexcg growth 3Y N/A
ROICexcg growth 5Y N/A ROICexc(3y) N/A
ROICexc growth 3Y N/A ROICexc growth 5Y N/A
OM growth 3Y N/A OM growth 5Y N/A
PM growth 3Y N/A PM growth 5Y N/A
GM growth 3Y -5.1% GM growth 5Y N/A
F-Score 2 Asset Turnover 0.27

Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 174.11%
Profit Quality N/A
Current Ratio 3.48
Quick Ratio 3.33
Altman-Z 2.45
F-Score 2 WACC 8.98%
ROIC/WACC N/A Cap/Depr(3y) 392.66%
Cap/Depr(5y) 787.68% Profit Quality(3y) N/A
Profit Quality(5y) N/A

Growth
EPS 1Y -29.65% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q -64.02%
EPS Next Y -35.43% EPS Next 2Y 9.26%
EPS Next 3Y 21.57% EPS Next 5Y 27.2%
Revenue growth 1Y 28.23% Revenue growth 3Y 124.22%
Revenue growth 5Y 78.04% Revenue growth Q2Q 40.86%
Revenue Next Year 23.25% Revenue Next 2Y 34.71%
Revenue Next 3Y 38.96% Revenue Next 5Y 35.97%
EBIT growth 1Y -11.67% EBIT growth 3Y N/A
EBIT growth 5Y N/A EBIT Next Year -6.19%
EBIT Next 3Y 30.89% EBIT Next 5Y 34.68%
FCF growth 1Y 18.52% FCF growth 3Y N/A
FCF growth 5Y N/A OCF growth 1Y 18.66%
OCF growth 3Y N/A OCF growth 5Y N/A

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA